Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 + cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer [1] [2] [3].
In Vivo, Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (100 μg, i.p., once every 3 days, for 2 dose) significantly reduces mXCL1-V21C/A59C induced CD8+ cytotoxic T cells (CTLs) tumor infiltration and partially reverses its anti-tumor effect in C57BL/6 mice bearing E.G7-OVA tumors or B16-F10 tumors[1]. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (200 μg, i.p., once every 2 days, until complete cessation of graft beating) significantly prolongs the survival time of transplanted hearts and inhibits T cell activation in male C57BL/6J mice[2]. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (250 μg, i.p., twice weekly, for 2 weeks) reduces the proportion of stem lines and increases the survival of side lines in male NPK mice with prostate cancer induced by Tamoxifen [3].
References:
[1]. Kamei M, et al. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells. Int J Cancer. 2024 Jun 15;154(12):2176-2188.
[2]. Chen Z, et al. Single-Cell RNA sequencing reveals immune cell dynamics and local intercellular communication in acute murine cardiac allograft rejection. Theranostics. 2022 Aug 29;12(14):6242-6257.
[3]. Tshering LF, et al. Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Dev Cell. 2023 Jun 19;58(12):1071-1086.e8.
In Vivo, Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (100 μg, i.p., once every 3 days, for 2 dose) significantly reduces mXCL1-V21C/A59C induced CD8+ cytotoxic T cells (CTLs) tumor infiltration and partially reverses its anti-tumor effect in C57BL/6 mice bearing E.G7-OVA tumors or B16-F10 tumors[1]. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (200 μg, i.p., once every 2 days, until complete cessation of graft beating) significantly prolongs the survival time of transplanted hearts and inhibits T cell activation in male C57BL/6J mice[2]. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (250 μg, i.p., twice weekly, for 2 weeks) reduces the proportion of stem lines and increases the survival of side lines in male NPK mice with prostate cancer induced by Tamoxifen [3].
References:
[1]. Kamei M, et al. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells. Int J Cancer. 2024 Jun 15;154(12):2176-2188.
[2]. Chen Z, et al. Single-Cell RNA sequencing reveals immune cell dynamics and local intercellular communication in acute murine cardiac allograft rejection. Theranostics. 2022 Aug 29;12(14):6242-6257.
[3]. Tshering LF, et al. Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Dev Cell. 2023 Jun 19;58(12):1071-1086.e8.